Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oragenics has filed a US patent application covering the intellectual property surrounding its small molecule anti-obesity agent LPT3-04.
Subscribe to our email newsletter
As a natural substance, LPT3-04 is orally available and has an excellent safety and tolerability profile. The technology is currently at a late discovery stage, and the company intends to continue development of this proprietary technology while it seeks a commercial partner actively involved in anti-obesity therapeutics.
Cell culture studies and specific animal models of obesity have been used to identify the primary mechanism of action for promoting weight loss. LPT3-04 appears to target fat cells and, specifically, induce apoptosis in white adipose cells. This effect occurs in a dose-dependent fashion. The new patent will cover all material on the agent and its analogs.
“Further scientific development remains before we can begin human clinical trials, but we are excited about the commercial potential for our novel small molecule, and its analogs, for regulation of body weight,” said Dr Robert Zahradnik, president and CEO of Oragenics.